English

Baudax Bio, Inc.

EDGAR

BXRX Filing (25-NSE) · filed 2024-02-15

27 filing records in this dataset, filed from 2019-11-14 to 2024-02-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-2.37 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -9680000 USD Source
Operating Cash Flow: -7310000 USD Source

Cash and cash equivalents: 363 thousand USD 2023-09-30 Source
Exact value

363000 USD
Long-term debt including current maturities: 4.23 million USD 2023-09-30 Source
Exact value

4228000 USD
Shares outstanding: 12.2 million shares 2023-09-30 Source
Exact value

12164753 shares

Reported share-count change

-39.19% · -7.84 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

20003745 shares · 2022-09-30· Source
12164753 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

354 thousand USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Revenue: 1269000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 959000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 14000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 30000 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 0 USD · 2023-07-01 – 2023-09-30 Source

Capital expenditure

147 thousand USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Capital expenditure: 76000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 76000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 203000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 76000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 20000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 20000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 20000 USD · 2022-01-01 – 2022-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-02-15.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 5 of 11 periods available· newest 2022-12-31
Net income: 5 of 11 periods available· newest 2022-12-31
Operating cash flow: 5 of 11 periods available· newest 2022-12-31
Capital expenditure: 5 of 11 periods available· newest 2022-12-31
Total assets: 3 of 11 periods available· newest 2022-12-31
Total liabilities: 3 of 11 periods available· newest 2022-12-31
Current assets: 3 of 11 periods available· newest 2022-12-31
Current liabilities: 3 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2022-12-31
Shares outstanding: 3 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+17.5%

Prior period

USD 1.08 million

2021-01-01 – 2021-12-31
Current period

USD 1.27 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

1269000 − 1080000 = 189000 USD

1080000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
1269000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Year-over-year change in Revenue: 189000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1269000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2064294 Filing: 000095017023003946 Input fundies:Revenue: 1080000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2066314 Filing: 000095017023003946
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 39.03 million

Prior period

−USD 19.77 million

2021-01-01 – 2021-12-31
Current period

−USD 58.8 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-58795000 − -19769000 = -39026000 USD

-19769000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-58795000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Year-over-year change in Net income: -39026000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -58795000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2700725 Filing: 000095017023003946 Input fundies:NetIncome: -19769000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2703006 Filing: 000095017023003946
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 21.48 million

Prior period

−USD 49.27 million

2021-01-01 – 2021-12-31
Current period

−USD 27.79 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-27793000 − -49270000 = 21477000 USD

-49270000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-27793000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Year-over-year change in Operating cash flow: 21477000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -27793000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2520370 Filing: 000095017023003946 Input fundies:OperatingCashFlow: -49270000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2522840 Filing: 000095017023003946
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-90.1%

Prior period

USD 203,000

2021-01-01 – 2021-12-31
Current period

USD 20,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

20000 − 203000 = -183000 USD

203000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
20000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Year-over-year change in Capital expenditure: -183000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 20000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2528740 Filing: 000095017023003946 Input fundies:CapitalExpenditure: 203000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2530948 Filing: 000095017023003946
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 1.27 million 100% of revenue
Cost of revenue USD 7.01 million 552% of revenue
Operating expenses USD 28.01 million 2,207% of revenue
Other operating costs Derived USD 23.07 million 1,818% of revenue
Operating income −USD 56.81 million −4,477% of revenue
Tax, interest and other Derived USD 1.98 million 156% of revenue
Net income −USD 58.8 million −4,633% of revenue

Cash

Operating cash flow −USD 27.79 million −2,190% of revenue
Capital expenditure USD 20,000 1.6% of revenue
Free cash flow Derived −USD 27.81 million −2,192% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 15,270% of revenue.
2021 Operating loss: operating costs were 1,860% of revenue.
2022 Operating loss: operating costs were 4,577% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	493000	75279000 Derived	-74786000	1314000 Derived	-76100000	-44697000 Derived	Source 2020-01-01 – 2020-12-31: 493000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -74786000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -76100000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -44058000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 639000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1080000	20086000 Derived	-19006000	763000 Derived	-19769000	-49473000 Derived	Source 2021-01-01 – 2021-12-31: 1080000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -19006000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -19769000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -49270000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 203000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1269000	58082000 Derived	-56813000	1982000 Derived	-58795000	-27813000 Derived	Source 2022-01-01 – 2022-12-31: 1269000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -56813000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -58795000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -27793000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 20000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.3M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	493000	Revenue: 493000 Open source
20212021-12-31	Revenue	1080000	Revenue: 1080000 Open source
20222022-12-31	Revenue	1269000	Revenue: 1269000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

17.5% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 493000 Open source
20212021-12-31	Year over year	119.1%	Revenue: 1080000 Open source Revenue: 493000 Open source
20222022-12-31	Year over year	17.5%	Revenue: 1269000 Open source Revenue: 1080000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,477% 2022

Net margin -4,633.2% 2022

Free cash flow margin -2,191.7% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-15,169.6%	Operating Income: -74786000 Open source Revenue: 493000 Open source
20212021-12-31	Operating margin	-1,759.8%	Operating Income: -19006000 Open source Revenue: 1080000 Open source
20222022-12-31	Operating margin	-4,477%	Operating Income: -56813000 Open source Revenue: 1269000 Open source
20202020-12-31	Net margin	-15,436.1%	Net Income: -76100000 Open source Revenue: 493000 Open source
20212021-12-31	Net margin	-1,830.5%	Net Income: -19769000 Open source Revenue: 1080000 Open source
20222022-12-31	Net margin	-4,633.2%	Net Income: -58795000 Open source Revenue: 1269000 Open source
20202020-12-31	Free cash flow margin	-9,066.3%	Revenue: 493000 Open source Operating Cash Flow: -44058000 Open source Capital Expenditure: 639000 Open source
20212021-12-31	Free cash flow margin	-4,580.8%	Revenue: 1080000 Open source Operating Cash Flow: -49270000 Open source Capital Expenditure: 203000 Open source
20222022-12-31	Free cash flow margin	-2,191.7%	Revenue: 1269000 Open source Operating Cash Flow: -27793000 Open source Capital Expenditure: 20000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -27.8M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-44058000	Operating Cash Flow: -44058000 Open source
20212021-12-31	Operating cash flow	-49270000	Operating Cash Flow: -49270000 Open source
20222022-12-31	Operating cash flow	-27793000	Operating Cash Flow: -27793000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -27.8M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-44697000	Operating Cash Flow: -44058000 Open source Capital Expenditure: 639000 Open source
20212021-12-31	Free cash flow	-49473000	Operating Cash Flow: -49270000 Open source Capital Expenditure: 203000 Open source
20222022-12-31	Free cash flow	-27813000	Operating Cash Flow: -27793000 Open source Capital Expenditure: 20000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

341.6% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	121.5%	Total Liabilities: 83532000 Open source Total Assets: 68733000 Open source
20212021-12-31	Liabilities / assets	75.2%	Total Liabilities: 40051000 Open source Total Assets: 53277000 Open source
20222022-12-31	Liabilities / assets	341.6%	Total Liabilities: 34274000 Open source Total Assets: 10032000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.3× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.03×	Current Assets: 36717000 Open source Current Liabilities: 18129000 Open source
20212021-12-31	Current assets / current liabilities	1.5×	Current Assets: 23494000 Open source Current Liabilities: 15646000 Open source
20222022-12-31	Current assets / current liabilities	0.3×	Current Assets: 6347000 Open source Current Liabilities: 21460000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 73.67 million Exact value Exact value: -73667000 USD 2018-01-01 – 2018-12-31: -73667000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Baudax Bio, Inc. · 2018-12-31 Baudax Bio, Inc. (edgar:1780097) Net Income: -73667000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73667000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459020004638/bxrx-20191231.xml#111371 Filing: 000156459020004638 The citation records this snapshot. The page link may show a newer release later.	−USD 59.75 million Exact value Exact value: -59751000 USD 2018-01-01 – 2018-12-31: -59751000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Baudax Bio, Inc. · 2018-12-31 Baudax Bio, Inc. (edgar:1780097) Operating Cash Flow: -59751000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59751000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459020004638/bxrx-20191231.xml#122333 Filing: 000156459020004638 The citation records this snapshot. The page link may show a newer release later.	USD 3.37 million Exact value Exact value: 3370000 USD 2018-01-01 – 2018-12-31: 3370000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Baudax Bio, Inc. · 2018-12-31 Baudax Bio, Inc. (edgar:1780097) Capital Expenditure: 3370000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3370000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459020004638/bxrx-20191231.xml#122755 Filing: 000156459020004638 The citation records this snapshot. The page link may show a newer release later.	−USD 63.12 million Calculation and evidence -59751000 − 3370000 USD Exact free cash flow: -63121000 USD 2018-01-01 – 2018-12-31: -59751000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 3370000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Baudax Bio, Inc. · 2018-12-31 Baudax Bio, Inc. (edgar:1780097) Free cash flow: -63121000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59751000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459020004638/bxrx-20191231.xml#122333 Filing: 000156459020004638 Input fundies:CapitalExpenditure: 3370000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459020004638/bxrx-20191231.xml#122755 Filing: 000156459020004638 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 32.56 million Exact value Exact value: -32557000 USD 2019-01-01 – 2019-12-31: -32557000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Baudax Bio, Inc. · 2019-12-31 Baudax Bio, Inc. (edgar:1780097) Net Income: -32557000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32557000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459021005901/bxrx-10k_20201231.htm#2311460 Filing: 000156459021005901 The citation records this snapshot. The page link may show a newer release later.	−USD 50.04 million Exact value Exact value: -50044000 USD 2019-01-01 – 2019-12-31: -50044000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Baudax Bio, Inc. · 2019-12-31 Baudax Bio, Inc. (edgar:1780097) Operating Cash Flow: -50044000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50044000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459021005901/bxrx-10k_20201231.htm#2128659 Filing: 000156459021005901 The citation records this snapshot. The page link may show a newer release later.	USD 1.32 million Exact value Exact value: 1319000 USD 2019-01-01 – 2019-12-31: 1319000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Baudax Bio, Inc. · 2019-12-31 Baudax Bio, Inc. (edgar:1780097) Capital Expenditure: 1319000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1319000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459021005901/bxrx-10k_20201231.htm#2136372 Filing: 000156459021005901 The citation records this snapshot. The page link may show a newer release later.	−USD 51.36 million Calculation and evidence -50044000 − 1319000 USD Exact free cash flow: -51363000 USD 2019-01-01 – 2019-12-31: -50044000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1319000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Baudax Bio, Inc. · 2019-12-31 Baudax Bio, Inc. (edgar:1780097) Free cash flow: -51363000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50044000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459021005901/bxrx-10k_20201231.htm#2128659 Filing: 000156459021005901 Input fundies:CapitalExpenditure: 1319000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000156459021005901/bxrx-10k_20201231.htm#2136372 Filing: 000156459021005901 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 76.1 million Exact value Exact value: -76100000 USD 2020-01-01 – 2020-12-31: -76100000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Baudax Bio, Inc. · 2020-12-31 Baudax Bio, Inc. (edgar:1780097) Net Income: -76100000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -76100000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017022003844/bxrx-20211231.htm#2048525 Filing: 000095017022003844 The citation records this snapshot. The page link may show a newer release later.	−USD 44.06 million Exact value Exact value: -44058000 USD 2020-01-01 – 2020-12-31: -44058000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Baudax Bio, Inc. · 2020-12-31 Baudax Bio, Inc. (edgar:1780097) Operating Cash Flow: -44058000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44058000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017022003844/bxrx-20211231.htm#2256380 Filing: 000095017022003844 The citation records this snapshot. The page link may show a newer release later.	USD 639,000 Exact value Exact value: 639000 USD 2020-01-01 – 2020-12-31: 639000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Baudax Bio, Inc. · 2020-12-31 Baudax Bio, Inc. (edgar:1780097) Capital Expenditure: 639000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 639000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017022003844/bxrx-20211231.htm#2263691 Filing: 000095017022003844 The citation records this snapshot. The page link may show a newer release later.	−USD 44.7 million Calculation and evidence -44058000 − 639000 USD Exact free cash flow: -44697000 USD 2020-01-01 – 2020-12-31: -44058000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 639000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Baudax Bio, Inc. · 2020-12-31 Baudax Bio, Inc. (edgar:1780097) Free cash flow: -44697000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44058000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017022003844/bxrx-20211231.htm#2256380 Filing: 000095017022003844 Input fundies:CapitalExpenditure: 639000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017022003844/bxrx-20211231.htm#2263691 Filing: 000095017022003844 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 19.77 million Exact value Exact value: -19769000 USD 2021-01-01 – 2021-12-31: -19769000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Baudax Bio, Inc. · 2021-12-31 Baudax Bio, Inc. (edgar:1780097) Net Income: -19769000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19769000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2703006 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.	−USD 49.27 million Exact value Exact value: -49270000 USD 2021-01-01 – 2021-12-31: -49270000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Baudax Bio, Inc. · 2021-12-31 Baudax Bio, Inc. (edgar:1780097) Operating Cash Flow: -49270000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49270000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2522840 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.	USD 203,000 Exact value Exact value: 203000 USD 2021-01-01 – 2021-12-31: 203000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Baudax Bio, Inc. · 2021-12-31 Baudax Bio, Inc. (edgar:1780097) Capital Expenditure: 203000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 203000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2530948 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.	−USD 49.47 million Calculation and evidence -49270000 − 203000 USD Exact free cash flow: -49473000 USD 2021-01-01 – 2021-12-31: -49270000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 203000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Baudax Bio, Inc. · 2021-12-31 Baudax Bio, Inc. (edgar:1780097) Free cash flow: -49473000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49270000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2522840 Filing: 000095017023003946 Input fundies:CapitalExpenditure: 203000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2530948 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 58.8 million Exact value Exact value: -58795000 USD 2022-01-01 – 2022-12-31: -58795000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Net Income: -58795000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58795000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2700725 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.	−USD 27.79 million Exact value Exact value: -27793000 USD 2022-01-01 – 2022-12-31: -27793000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Operating Cash Flow: -27793000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27793000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2520370 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.	USD 20,000 Exact value Exact value: 20000 USD 2022-01-01 – 2022-12-31: 20000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Capital Expenditure: 20000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 20000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2528740 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.	−USD 27.81 million Calculation and evidence -27793000 − 20000 USD Exact free cash flow: -27813000 USD 2022-01-01 – 2022-12-31: -27793000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 20000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Baudax Bio, Inc. · 2022-12-31 Baudax Bio, Inc. (edgar:1780097) Free cash flow: -27813000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1780097?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27793000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2520370 Filing: 000095017023003946 Input fundies:CapitalExpenditure: 20000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1780097/000095017023003946/bxrx-20221231.htm#2528740 Filing: 000095017023003946 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

27 filings · 1,215 latest values · 1,215 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001780097, 1780097, BXRX, edgar:1780097

Also known as Baudax Bio, Inc, Baudax Bio, Inc., Recro Enterprises, Inc.

Baudax Bio, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation